Dr. Jhaveri on Acquired Resistance to CDK 4/6 Inhibitors in Breast Cancer

Video

In Partnership With:

Komal L. Jhaveri, MD, FACP, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses acquired resistance to CDK 4/6 inhibitors in breast cancer.

Komal L. Jhaveri, MD, FACP, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses acquired resistance to CDK 4/6 inhibitors in breast cancer.

Preclinical data may justify combination regimens to address acquired resistance to CDK 4/6 inhibitors, says Jhaveri. Some adaptive responses to CDK 4/6 inhibition may lead to activation of the PI3K pathway. That, Jhaveri says, has justified a triplet combination to be evaluated in the clinic. That is an ongoing effort.

Some data suggest that FGFR1 amplification could be 1 mechanism of resistance. An early data set from the MONALEESA-2 trial showed that FGFR1 amplification from baseline circulating tumor DNA has limited progression-free survival benefit. Though small in number, Jhaveri says it parallels the data that show that FGFR1 amplification is a resistance mechanism.

Related Videos
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center
I-Chia (Daniel) Liu, MD
Robert W. Mutter, MD